Axelopran for Cancer

(AxeCan Trial)

This trial aims to test whether axelopran, a new potential drug, can slow tumor growth and improve quality of life in patients with advanced cancers of the lung, breast, pancreas, or prostate. Researchers seek to determine if axelopran is safe for long-term use and if it can improve bowel function and reduce inflammation. Ideal participants are those whose cancer has returned or worsened after standard treatments and who currently use opioid medication daily. Participants will take axelopran pills daily and attend regular study visits, which include medical tests and surveys. As a Phase 2 trial, this research measures how well axelopran works in an initial, smaller group of people, offering participants the chance to contribute to important findings.

You may need to stop taking certain medications to join the trial. Specifically, you cannot use buprenorphine, alvimopan, naltrexone, methylnaltrexone, naloxone, lubiprostone, linaclotide, or tapentadol within 14 days before enrolling, and you must avoid certain other medications like strong CYP3A4 inhibitors and inducers. It's best to discuss your current medications with the trial team to see if any changes are needed.

Research has shown that axelopran has been tested in studies to evaluate its effectiveness with cancer treatments known as checkpoint inhibitors. These studies found that axelopran can help shrink tumors and boost the immune system. They also assessed the safety and tolerability of axelopran for patients.

Although detailed information on side effects from these studies is not available, the testing of axelopran with advanced cancer patients suggests it demonstrated some level of safety in earlier research. Generally, if a treatment reaches this testing phase, it indicates positive signs of safety and tolerability in earlier stages.

Axelopran is unique because it represents a novel approach in cancer treatment with its specific mechanism of action. Unlike standard chemotherapy treatments that target rapidly dividing cells broadly, Axelopran is designed to target specific pathways involved in cancer cell survival and growth. This targeted approach may offer a more precise treatment option, potentially reducing side effects and improving effectiveness. Researchers are excited about Axelopran because it could lead to better outcomes for patients with fewer complications than traditional cancer therapies.

Research has shown that axelopran, administered as monotherapy in this trial, may slow tumor growth and improve the quality of life for cancer patients. In animal studies, axelopran counteracted the negative effects of opioids on the immune system, which is crucial for cancer treatment. It has also been tested in various cancers, such as lung cancer, and may reduce inflammation and related symptoms. This suggests it might help manage cancer-related issues like bowel function and overall well-being. Although more data from human trials is needed, early results are promising.²³⁶⁷⁸